Antimicrobial Drug Approvals Should Include Pathogen-Specific Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA should be granted authority to approve antimicrobial drugs based on the pathogens they target rather than infection types.
You may also be interested in...
Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets
Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia
Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets
Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia
Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets
The Lexington, Mass., biotech plans to start CXA-201 in HAP/VAP soon depending on how FDA guidance - due by the end of the year - plays out.